EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study

Narisara Phansila iD, Paopong Pansila, Adisorn Wongkongdech iD, Niruwan Turnbull iD, Mahalul Azam iD, Ranee Wongkongdech iD

F1000Research · 2025

DOI: 10.12688/f1000research.123250.3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift F1000Research, 2025. Verfasst von Narisara Phansila und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chiang Kwan Hospital, Roi-et Province, 45000, Thailand. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Medical Marijuana, Bile Duct Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mahasarakham University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cholangiocarcinoma (CCA) incidence in Northeastern Thailand is very high and a major cause of mortality. CCA patients typically have a poor prognosis and short-term survival rate due to late-stage diagnosis. Thailand is the first Southeast Asian country to approve medicinal cannabis treatment, especially for palliative care with advanced cancer patients.

Methods

A retrospective cohort study compared survival among 491 newly diagnosed advanced CCA patients between September 2019 and June 2021. Of these, 404 received standard palliative pain management (ST), and 87 received medicinal cannabis treatment (CT). Patients were enrolled from four tertiary hospitals and two secondary hospitals in five provinces of Northeast Thailand. Cumulative survival was calculated by the Kaplan-Meier method, and independent prognostic factors were analyzed using Cox regression.

Results

For ST patients, follow-up time was 790 person-months, with a mortality rate of 48.35/100 person-months. For CT patients, follow-up time was 476 person-months, with a mortality rate of 10.9/100 person-months. The median survival time after registration at a palliative clinic was 0.83 months (95% CI: 0.71–0.95) for ST and 5.66 months (95% CI: 1.94–9.38) for CT. Multivariate analysis showed CT was significantly associated with prolonged survival (HRadj = 0.28; 95% CI: 0.20–0.37; p < 0.001).

Conclusions

The medical cannabis increased overall survival rates among CCA patients. In this retrospective cohort, Medicinal cannabis treatment was associated with more prolonged survival among advanced CCA patients in Northeastern Thailand. While this association remained significant after multivariable adjustment, unmeasured or residual confounding factors may have influenced the observed outcomes. Although the association remained significant after adjustment, unmeasured or residual confounders may have influenced outcomes. Further prospective studies are warranted to confirm these findings and explore potential mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaMedical MarijuanaBile Duct NeoplasmsCarcinoma, HepatocellularHumansRetrospective StudiesMaleFemaleMiddle AgedThailandAgedSurvival RatePalliative CareAdultPrognosis

Stichwörter der Autor:innen

Northeastern ThailandSurvival ratecHCC-CCcombined hepatocellular cholangiocarcinomamedicinal cannabispalliative care

Substanzen

Medical Marijuana

Autor:innen und Institutionen

  • Chiang Kwan Hospital, Roi-et Province, 45000, Thailand.
  • Faculty of Medicine, Mahasarakham University, Mahasarakham, 44000, Thailand.
  • Faculty of Public Health, Mahasarakham University, Mahasarakham, Mahasarakham Province, 44150, Thailand.
  • Public Health and Environmental Policy in Southeast Asia Research Cluster (PHEP SEA Thailand), Mahasarakham University, Mahasarakham, 44150, Thailand.
  • Public Health Department, Faculty of Sport Sciences, Universitas Negeri Semarang, Semarang, 50229, Indonesia.
  • International and National Collaborative Network and Innovation for Community Health Development Research Unit (INCNI-CHD), Mahasarakham University, Mahasarakham, 44000, Thailand.

ORCID-Profile: Narisara Phansila, Adisorn Wongkongdech, Niruwan Turnbull, Mahalul Azam, Ranee Wongkongdech

Förderung

  • Mahasarakham University

Zitieren

APA

Phansila, N., Pansila, P., Wongkongdech, A., Turnbull, N., Azam, M., & Wongkongdech, R. (2025). Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study. F1000Research. https://doi.org/10.12688/f1000research.123250.3

Vancouver

Phansila N, Pansila P, Wongkongdech A, Turnbull N, Azam M, Wongkongdech R. Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study. F1000Research. 2025. doi:10.12688/f1000research.123250.3

BibTeX
@article{Phansila2025,
  author = {Phansila, Narisara and Pansila, Paopong and Wongkongdech, Adisorn and Turnbull, Niruwan and Azam, Mahalul and Wongkongdech, Ranee},
  title = {Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study},
  journal = {F1000Research},
  year = {2025},
  doi = {10.12688/f1000research.123250.3}
}
Kostenlos starten →